Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AstraZeneca (LSE:AZN): Oncology Momentum and 12 Phase III Wins Shape Its Nine-Month Update

AstraZeneca PLC (LSE:AZN) shares rose 0.29% to 14,022p on 16 Nov 2026, leaving the global biopharmaceutical group marginally higher on the London market. A move of this kind is best viewed in context, because daily price changes can be influenced by market-wide sentiment, currency …

Divya Sood | 16 November 2026

Convatec (LSE:CTEC): New Product Launches, a USD 200 Million Buyback and a Margin Step-Up Planned for H2

Convatec Group PLC (LSE:CTEC) shares rose 0.31% to 259p on 16 Nov 2026, leaving the medical products group marginally higher on the London market. Share price movements over a single session are frequently shaped by broader market conditions, changes in investor positioning and sector-wide …

Divya Sood | 16 November 2026

What Creo Medical's interim results signal for its FTSE AIM All Share Index future (LSE:CREO)

Creo Medical develops devices used by clinicians in minimally invasive procedures. Its best-known product is the Speedboat device, which the company says has now been used in more than 10,000 procedures. It has also been commercialising its MicroBlate range, announcing in July 2026 that …

Divya Sood | 16 November 2026

Why CRISM Therapeutics (LSE:CRTX) Is Entering a Key Clinical Phase Within the FTSE AIM All Share Index

CRISM Therapeutics is a UK-focused clinical-stage company developing ChemoSeed, an implantable and biodegradable platform designed to deliver chemotherapy directly to tumours in a localised and sustained way. Its lead candidate is irinotecan-ChemoSeed, which is intended to be implanted during surgery for glioblastoma, an aggressive …

Divya Sood | 16 November 2026

How Diaceutics (LSE:DXRX) is building recurring revenue within the FTSE AIM All Share Index

Diaceutics works with pharmaceutical companies to help precision medicines reach the patients who can benefit from them. Precision medicines often depend on a diagnostic test to identify eligible patients, and Diaceutics supports this process through data, analytics and services that span diagnostic regulatory planning, …

Divya Sood | 16 November 2026

How ECO Animal Health Group (LSE:EAH) is building a vaccine pipeline as China sales slow in the FTSE AIM All Share Index

ECO Animal Health develops and sells medicines and vaccines for farm animals, with poultry an important market. Its established product is Aivlosin, an antibiotic used in livestock, and it is now building a range of poultry vaccines under the ECOVAXXIN brand. The group sells …

Divya Sood | 16 November 2026

What EDX Medical Group (LSE:EDX) is building in diagnostics within the FTSE AIM All Share Index

EDX Medical is a diagnosticsBusinesswith a portfolio of testing services covering cancer, infectious disease and wider health screening. Its announcements during 2026 describe a model built on partnerships, supplying tests developed in-house or by third parties to the NHS, private healthcare providers and employers.

Divya Sood | 16 November 2026

How Feedback (LSE:FDBK) Is Pursuing NHS Contracts With Its Bleepa Platform

Feedback develops digital health technology for the NHS. Its main product, Bleepa, is a clinical communication and care pathway platform that lets clinicians share information, including medical images, and manage patients along defined pathways.

Ankur Sharma | 16 November 2026

What Fusion Antibodies (LSE:FAB) Is Doing as It Wins Repeat Work and Reviews Working Capital

Fusion Antibodies provides contract services to pharmaceutical and biotechnology companies, including antibody discovery, cell line development, transient gene expression and structural studies such as cryogenic electron microscopy. It also runs grant-funded projects with Queen's University Belfast.

Ankur Sharma | 16 November 2026

How Faron Pharmaceuticals (LSE:FARN) Is Preparing Its Bexmarilimab Data for ASH

Faron is based in Turku, Finland, and is listed on both AIM andNasdaqFirst North in Helsinki. Its lead asset, bexmarilimab, is a humanised antibody that targets Clever-1, a receptor found on certain immune cells. The company is studying it in blood cancers and solid …

Ankur Sharma | 16 November 2026
Support

Hi! How can we help you today?

Loading…